Athersys (Athersys) Insider Ownership : 7.10 % (As of May. 28, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Athersys Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Athersys's insider ownership is 7.10%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Athersys's Institutional Ownership is 0.03%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Athersys's Float Percentage Of Total Shares Outstanding is 99.31%.

Athersys Insider Ownership Historical Data

The historical data trend for Athersys's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Insider Ownership Chart

Athersys Historical Data

The historical data trend for Athersys can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Insider Ownership	21.14	16.51	16.51	16.41	7.10	7.10	7.10	7.10	7.10	7.10

Athersys Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Athersys (Athersys) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634

Website

https://www.athersys.com

Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Executives

Neema Mayhugh	director	3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan	director	100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo	director, officer: Chief Executive Officer	ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen	officer: Chief Operating Officer	16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado	officer: Interim, CFO	485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod	officer: Chief Financial Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann	officer: President	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington	director, officer: Chief Scientific Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell	officer: Vice President	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah	director	ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub	director
Tadahisa Kagimoto	director, 10 percent owner	HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115